As a result, the survival benefits of increased CTL levels were more likely to be occurred in the CDC20-high cases, but not the CDC20-low patients in melanoma, lung cancer, breast cancer, as well as head and neck cancer (Additional file : 2Fig. S4). This evidence concerns the gene CDC20 and breast cancer.